Testing a new gene therapy for nerve pain that doesn't respond to standard treatments

This is an early-stage study testing ST-503, a new type of treatment called gene therapy, for people with small fiber neuropathy—a condition where small nerve fibers in the skin are damaged, causing burning pain and tingling sensations. The medication is delivered directly into the fluid around your spinal cord through a single injection. The trial's main goal is to make sure this treatment is safe; a secondary goal is to see whether it can reduce pain that hasn't gotten better with standard medications.

Small fiber neuropathy can cause severe, ongoing pain that doesn't respond well to conventional pain medications, leaving many patients without good treatment options. This medication works differently by using gene therapy to target specific proteins in nerve cells that send pain signals, offering a potentially new way to help people with this hard-to-treat condition.